Gate2brain Achieves Emerging Company Certification from Enisa
Gate2brain S.L. has proudly received the Emerging Company Certification issued by the Ministry of Industry and Tourism through ENISA (Empresa Nacional de Innovación SME, S.A.). This certification not only acknowledges Gate2brain’s commitment to innovation but also highlights its potential as a scalable enterprise in today’s competitive market.
A Milestone in Innovation
The recent certification comes as part of the “Law for the Promotion of the Emerging Companies Ecosystem” – widely known as the “Startup Law.” This groundbreaking legislation introduces a comprehensive set of measures aimed at facilitating the creation and growth of emerging companies while promoting investment in innovation.
What This Certification Means for Gate2brain
For Gate2brain, receiving the Emerging Company Certification is a testament to its innovative spirit and scalable business model. As a company committed to transforming research into impactful solutions, this recognition provides a strong endorsement of its entrepreneurial drive.
Looking Ahead
This achievement marks an exciting new chapter for Gate2brain. With the support of ENISA and the strategic advantages offered by the Startup Law, the company is set to accelerate its innovation journey.
This certification reinforces the company’s status as a promising and forward-looking enterprise, ready to make a significant impact in the healthcare industry.
About Gate2Brain
Gate2Brain is a technology platform spin off from IRB Barcelona, the University of Barcelona, and the Sant Joan de Déu Hospital, founded in 2020. Gate2Brain uses its proprietary peptide-based technology to cross biological barriers, such as the blood–brain barrier, to improve drug delivery to the brain and reduce side effects. With a first asset in pediatric brain tumors, Gate2Brain has demonstrated the expansion of the potential use of the G2B technology to other drug modalities.
The company has received support from institutions including Fundación Botín (Mind the Gap), Banco Sabadell (BStartup Health), CDTI- Ministerio de Ciencia e Innovación, European Union (Next Generation EU), the European Innovation Council (EIC Accelerator), Startup Capital d’ACCIÓ, and CaixaResearch Consolidate de la Fundació “la Caixa”.
Gate2Brain envisions improving patients’ quality of life through technology that enhances drug delivery efficiency.
